BioStock analyzes CombiGene
BioStock today publishes its first analysis of CombiGene. In the analysis, BioStock writes, among other things:
“Given the progress CombiGene has made so far, the company is an attractive target for possible acquisitions and licensing deals in the coming years. The fact that CombiGene is also the only listed company on the Swedish stock market and with a niche exposure in the fast-growing gene therapy area, we regard as an exclusive position.”
CombiGene’s vision is to provide patients affected by severe life-altering diseases with the prospect of a better life through novel gene therapies. CombiGene’s business concept is to develop effective gene therapies for severe life-altering diseases where adequate treatment is currently lacking. Development assets are sourced from an external research network and developed to achieve clinical proof of concept. Drug candidates for common diseases will be co-developed and commercialized through strategic partnerships, while the company may manage this process on its own for drugs targeting niched patient populations. The company is public and listed on the Swedish marketplace Nasdaq First North Growth Market and the company’s Certified Advisor is FNCA Sweden AB, +46 (0)852 80 03 99 email@example.com.